Literature DB >> 17698697

Treatment options in the modern management of Parkinson disease.

Anthony H V Schapira1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17698697     DOI： 10.1001/archneur.64.8.1083

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  26 in total

Review 1.  Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Authors:  Anthony H V Schapira
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 2.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 3.  Modern treatment in Parkinson's disease, a personal approach.

Authors:  Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-21       Impact factor: 3.575

Review 4.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

5.  Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers.

Authors:  Andrea Francesco Daniele Di Stefano; Antonio Rusca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-08-19       Impact factor: 3.000

Review 6.  Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.

Authors:  Mark Sanford; Lesley J Scott
Journal:  CNS Drugs       Date:  2011-08       Impact factor: 5.749

7.  Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care.

Authors:  A Antonini; P Odin; L Opiano; V Tomantschger; C Pacchetti; B Pickut; U E Gasser; D Calandrella; F Mancini; M Zibetti; B Minafra; I Bertaina; P De Deyn; C Cras; E Wolf; S Spielberger; W Poewe
Journal:  J Neural Transm (Vienna)       Date:  2013-04-18       Impact factor: 3.575

8.  Evaluation of selective human MAO inhibitory activities of some novel pyrazoline derivatives.

Authors:  Umut Salgin-Gökşen; Samiye Yabanoğlu-Çiftçi; Ayşe Ercan; Kemal Yelekçi; Gülberk Uçar; Nesrin Gökhan-Kelekçi
Journal:  J Neural Transm (Vienna)       Date:  2013-01-30       Impact factor: 3.575

9.  Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis.

Authors:  Florent F Richy; Guilhem Pietri; Kimberly A Moran; Emmanuelle Senior; Lydia E Makaroff
Journal:  Appl Health Econ Health Policy       Date:  2013-08       Impact factor: 2.561

10.  Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl]carbamic acid with tyrosine hydroxylase.

Authors:  Zahida Parveen; Muhammad Sulaman Nawaz; Shazi Shakil; Nigel H Greig; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.